You have free access to this content

Cancer

Cover image for Vol. 115 Issue 1

1 January 2009

Volume 115, Issue 1

Pages 1–232

  1. News

    1. Top of page
    2. News
    3. Commentary
    4. Editorial
    5. Review Articles
    6. Original Articles
    1. You have free access to this content
      CancerScope (pages 1–3)

      Carrie Printz

      Article first published online: 18 DEC 2008 | DOI: 10.1002/cncr.23998

  2. Commentary

    1. Top of page
    2. News
    3. Commentary
    4. Editorial
    5. Review Articles
    6. Original Articles
    1. You have free access to this content
      Timing of consent for the research use of surgically removed tissue : Is Postoperative Consenting Acceptable? (pages 4–9)

      Robert Hewitt, Peter H. Watson, Rajiv Dhir, Roger Aamodt, Gerry Thomas, Dan Mercola, William E. Grizzle and Manuel M. Morente

      Article first published online: 17 DEC 2008 | DOI: 10.1002/cncr.23999

      Consent by patients to perform surgery (‘surgical consent’) and consent for the research use of residual tissue (‘research consent’) are desirable to respect individual autonomy and human dignity. In the past, documentation of these consents has been conveniently obtained before surgery by the same person using the same form. More recently, however, ethical concerns have forced a separation between the 2 consents so that they are now often obtained by different people using different forms, thus raising the possibility of obtaining the research consent postoperatively. The current study seeks to clarify the issues and explain why a postoperative informed consent process has distinct advantages in certain circumstances.

  3. Editorial

    1. Top of page
    2. News
    3. Commentary
    4. Editorial
    5. Review Articles
    6. Original Articles
    1. You have free access to this content
      Sex and race in bladder cancer: What we have learned and future directions (pages 10–12)

      Mark H. Katz and Gary D. Steinberg

      Article first published online: 17 DEC 2008 | DOI: 10.1002/cncr.23997

      After controlling for prognostic variables, women and African Americans present with more advanced bladder cancer and have worse cancer-specific survival than other patient populations. Clinicians must focus on social factors influencing this disparity and on increasing public awareness and education to help standardize the diagnosis and management of bladder cancer for all patients.

  4. Review Articles

    1. Top of page
    2. News
    3. Commentary
    4. Editorial
    5. Review Articles
    6. Original Articles
    1. You have free access to this content
      Murine bone marrow–derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors (pages 13–22)

      Xiaoping Duan, Hui Guan, Ying Cao and Eugenie S. Kleinerman

      Article first published online: 2 DEC 2008 | DOI: 10.1002/cncr.24013

      Isolated murine mesenchymal stem cells can be transfected with the interleukin-12 (IL-12) gene. These transfected cells localize to tumors after intravenous injection and induce local IL-12 protein production and the regression of established tumors.

    2. You have free access to this content
      Acute leukemia as a secondary malignancy in children and adolescents: Current findings and issues (pages 23–35)

      Nobuko Hijiya, Kirsten K. Ness, Raul C. Ribeiro and Melissa M. Hudson

      Article first published online: 15 DEC 2008 | DOI: 10.1002/cncr.23988

      The results from this review indicated that the risk of secondary acute myeloid leukemia (s-AML) is influenced by various factors such as treatment variables, the schedule of administration, concomitant medications, host factors, and primary tumors. The authors also conducted a novel, mortality-based analysis of the risk-benefit ratio of epipodophyllotoxin, and they discuss recent findings on s-ALL and its treatment.

  5. Original Articles

    1. Top of page
    2. News
    3. Commentary
    4. Editorial
    5. Review Articles
    6. Original Articles
    1. Disease Site

      Gastrointestinal Disease
      You have free access to this content
      Mammary serine protease inhibitor inhibits epithelial growth factor-induced epithelial-mesenchymal transition of esophageal carcinoma cells (pages 36–48)

      Zhen Cai, Yuan Zhou, Ting Lei, Jen-Fu Chiu and Qing-Yu He

      Article first published online: 17 DEC 2008 | DOI: 10.1002/cncr.23991

      The metastasis-suppressive effect of mammary serine protease inhibitor (maspin) was studied by reintroducing maspin gene into a maspin-null esophageal cancer cell line, and the underlying mechanisms were further investigated. Maspin reintroduction led to a reversal of the malignant phenotype and a switch of cellular metabolic phenotype to low glycolysis, which indicate a new direction for future mechanism studies of maspin.

    2. You have free access to this content
      Promoter methylation of the Wnt/β-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer (pages 49–60)

      Jun Yu, Qian Tao, Yuen Y. Cheng, Kwan Y. Lee, Simon S. M. Ng, Kin F. Cheung, Linwei Tian, Sun Y. Rha, Ulf Neumann, Christoph Röcken, Matthias P. A. Ebert, Francis K. L. Chan and Joseph J. Y. Sung

      Article first published online: 2 DEC 2008 | DOI: 10.1002/cncr.23989

      The authors investigated promoter methylation of the dickkopf homolog 3 gene Dkk-3 and its prognostic significance in digestive cancers. The results indicated that epigenetic silencing of the Dkk-3 gene by promoter methylation was a common event in patients with gastric cancer and was associated with a poor outcome.

    3. Genitourinary Disease
      You have free access to this content
      Sequential therapy with sorafenib and sunitinib in renal cell carcinoma (pages 61–67)

      Arkadiusz Z. Dudek, Jakub Zolnierek, Anu Dham, Bruce R. Lindgren and Cezary Szczylik

      Article first published online: 2 DEC 2008 | DOI: 10.1002/cncr.24009

      In a retrospective analysis of 49 patients with metastatic renal cell carcinoma, second-line tyrosine kinase inhibitor (TKI) therapy using sorafenib or sunitinib was effective at achieving disease control after first-line TKI failure using the other agent. Sorafenib followed by sunitinib appeared to be more effective at disease control than the reverse sequence as indicated by a reduced time to disease progression (78 vs 37 weeks) and overall survival (102 vs 45 weeks).

    4. You have free access to this content
      Sex and racial differences in bladder cancer presentation and mortality in the US (pages 68–74)

      Emil Scosyrev, Katia Noyes, Changyong Feng and Edward Messing

      Article first published online: 15 DEC 2008 | DOI: 10.1002/cncr.23986

      Significant differences in tumor characteristics and age at presentation did not fully account for the excess hazard of death from bladder cancer among women and African American patients in this study. Other factors, such as choice and efficacy of therapies, differences within a given tumor characteristic group, and/or host factors, also may play important roles.

    5. Head and Neck Disease
      You have free access to this content
      Hyalinizing clear cell carcinoma : Case series and comprehensive review of the literature (pages 75–83)

      Antonieta A. Solar, Brian L. Schmidt and Richard C. K. Jordan

      Article first published online: 3 NOV 2008 | DOI: 10.1002/cncr.23974

      The authors analyzed 44 reported patients with hyalinizing clear cell carcinoma and included another 8 patients from their archives. The most significant finding of this review was the high rate of cervical lymph node metastasis, which implies that this entity is less indolent than previously believed; therefore, it may be necessary to consider including neck dissection in the primary management of this tumor.

    6. Hematologic Malignancies
      You have free access to this content
      Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan : A Randomized Phase 2 Trial by the Cancer and Leukemia Group B (CALGB 19803) (pages 84–93)

      David L. Grinblatt, Daohai Yu, Vera Hars, James W. Vardiman, Bayard L. Powell, Sreenivasa Nattam, Lewis R. Silverman, Carlos de Castro III, Richard M. Stone, Clara D. Bloomfield, Richard A. Larson and for the Cancer and Leukemia Group B

      Article first published online: 17 NOV 2008 | DOI: 10.1002/cncr.23995

      A randomized phase 2 trial of 2 doses and schedules or oral topotecan was conducted by the Cancer and Leukemia Group B in 90 patients with myelodysplastic syndrome. The response rate was modest (overall response rate, 30%), and significant toxicity was noted.

    7. You have free access to this content
      Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion : Report From the Polish Adult Leukemia Group (pages 94–100)

      Tadeusz Robak, Jerzy Z. Blonski, Ewa Wawrzyniak, Joanna Gora-Tybor, Aleksandra Palacz, Anna Dmoszynska, Lech Konopka, Krzysztof Warzocha and Krzysztof Jamroziak

      Article first published online: 24 NOV 2008 | DOI: 10.1002/cncr.24003

      The 17p13.1 deletion that causes loss of the p53-encoding TP53 gene is the most powerful predictor of a poor response to conventional therapy and shortened survival in patients with chronic lymphocytic leukemia. The results of this study have demonstrated that the cladribine and cyclophosphamide regimen may improve treatment results in this poor-risk patient population.

    8. You have free access to this content
      Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens (pages 101–106)

      Dushyant Verma, Susan O'Brien, Deborah Thomas, Stefan Faderl, Charles Koller, Sherry Pierce, Partow Kebriaei, Guillermo Garcia-Manero, Jorge Cortes, Hagop Kantarjian and Farhad Ravandi

      Article first published online: 17 DEC 2008 | DOI: 10.1002/cncr.24005

      Secondary acute myelogenous leukemia and myelodysplastic syndrome occur infrequently (2.49%) in adult acute lymphoblastic leukemia (ALL) patients treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens, and develop at a median of 32 months after ALL diagnosis. The median overall survival is 9.25 months.

    9. Lung Disease
      You have free access to this content
      Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas (pages 107–118)

      Yoh Dobashi, Shioto Suzuki, Hirochika Matsubara, Maiko Kimura, Shunsuke Endo and Akishi Ooi

      Article first published online: 17 DEC 2008 | DOI: 10.1002/cncr.23996

      In lung carcinomas, the mammalian target of rapamycin (mTOR) may play dual roles in the morphogenesis of adenocarcinoma and in metastasis of squamous cell carcinoma. The results from the current study suggest the potential of mTOR inhibitor as an additional component of chemotherapeutic regimens for patients with lung carcinoma.

    10. Melanoma
      You have free access to this content
      Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma : A North Central Cancer Treatment Group study, N047A (pages 119–127)

      Domingo G. Perez, Vera J. Suman, Tom R. Fitch, Thomas Amatruda III, Roscoe F. Morton, Shamim Z. Jilani, Costas L. Constantinou, James R. Egner, Lisa A. Kottschade and Svetomir N. Markovic

      Article first published online: 17 DEC 2008 | DOI: 10.1002/cncr.23987

      The authors report the results of a single-arm phase 2 clinical trial of the combination of paclitaxel, carboplatin, and bevacizumab for the treatment of metastatic melanoma. Treatment was well tolerated and yielded a median progression-free survival of 6 months, with a median overall survival of 12 months. These data are encouraging and strongly support further investigations into this treatment combination.

    11. You have free access to this content
      Tumor vasculature-targeted delivery of tumor necrosis factor-α (pages 128–139)

      Anita Tandle, Engy Hanna, Dominique Lorang, Amin Hajitou, Catherine A. Moya, Renata Pasqualini, Wadih Arap, Asha Adem, Elizabeth Starker, Stephen Hewitt and Steven K. Libutti

      Article first published online: 17 DEC 2008 | DOI: 10.1002/cncr.24001

      Tumor necrosis factor-α (TNF-α) was delivered specifically to tumor vasculature by using a hybrid adeno-associated virus phage vector to reduce its systemic toxicity. Because TNF-α is a promising antivascular agent that currently is limited by its toxicity, the results from this study suggested the potential for clinical translation of this strategy.

    12. Neuro-Oncology
      You have free access to this content
      Prognostic significance of c-Met expression in glioblastomas (pages 140–148)

      Doo-Sik Kong, Sang-Yong Song, Duk-Hwan Kim, Kyeung Min Joo, Jin-San Yoo, Jong Sung Koh, Seung Myung Dong, Yeon-Lim Suh, Jung-Il Lee, Kwan Park, Jong Hyun Kim and Do-Hyun Nam

      Article first published online: 30 OCT 2008 | DOI: 10.1002/cncr.23972

      c-Met overexpression is associated with shorter survival time and poor treatment response in patients with glioblastomas, the mechanism for which is elevated tumor invasiveness on the molecular and clinical phenotypes. This implies that more effective therapeutic strategies targeting c-Met receptors may have significant clinical implications.

    13. Sarcoma
      You have free access to this content
      Influence of compartmental involvement on the patterns of morbidity in soft tissue sarcoma of the thigh (pages 149–157)

      Andreas Rimner, Murray F. Brennan, Zhigang Zhang, Samuel Singer and Kaled M. Alektiar

      Article first published online: 17 DEC 2008 | DOI: 10.1002/cncr.23975

      This study sought to determine whether differences exist in patterns of outcome and morbidity between the 3 thigh compartments after limb-sparing surgery and postoperative radiation therapy in 255 patients with primary soft tissue sarcoma of the thigh. Although tumor control was similar for all 3 compartments, more wound reoperation and edema were observed in the medial compartment, and more nerve damage was noted in the posterior compartment.

    14. Skin
      You have free access to this content
      A retrospective review of 1349 cases of sebaceous carcinoma (pages 158–165)

      Tina Dasgupta, Lynn D. Wilson and James B. Yu

      Article first published online: 5 NOV 2008 | DOI: 10.1002/cncr.23952

      Sebaceous carcinoma is a rare and aggressive cutaneous carcinoma. An analysis of the National Cancer Institute's Surveillance, Epidemiology, and End Results database from 1973 to 2004 was performed, and new demographic and clinical insights were revealed.

    15. Discipline

      Disparities Research
      You have free access to this content
      Disparities in survival among women with invasive cervical cancer : A problem of access to care (pages 166–178)

      Kathleen F. Brookfield, Michael C. Cheung, Joseph Lucci, Lora E. Fleming and Leonidas G. Koniaris

      Article first published online: 18 DEC 2008 | DOI: 10.1002/cncr.24007

      In this study, race, ethnic, and socioeconomic disparities in cervical cancer survival were explained by late-stage presentation and under-treatment. Earlier diagnosis and greater access to surgery and other treatments would significantly improve the survival of women with cervical cancer.

    16. You have free access to this content
      Family history of cancer predicts Papanicolaou screening behavior for African American and white women (pages 179–189)

      Karen Patricia Williams, Paul Reiter, Athur Mabiso, Joel Maurer and Electra Paskett

      Article first published online: 24 NOV 2008 | DOI: 10.1002/cncr.23994

      A family history of any cancer is a strong predictor of Papanicolaou (Pap) screening behaviors in both African American and white women. Women with a family history of any cancer were 42% (P < .0001) more likely to have had a recent Pap test, with African American women being 53% (P < .0002) more likely, compared with 41% (P < .0001) for white women.

    17. Epidemiology
      You have free access to this content
      Indoor tanning use among adolescents in the US, 1998 to 2004 (pages 190–198)

      Vilma Cokkinides, Martin Weinstock, DeAnn Lazovich, Elizabeth Ward and Michael Thun

      Article first published online: 10 DEC 2008 | DOI: 10.1002/cncr.24010

      The prevalence of indoor tanning use in youths did not markedly change between 1998 and 2004, despite increasing numbers of states with legislation restricting youth access to indoor tanning. This suggests the need to develop multipronged approaches that could enhance changes in this behavior among underage minors.

    18. Medical Oncology
      You have free access to this content
      Herpes simplex virus lower respiratory tract infection in patients with solid tumors (pages 199–206)

      Galbiel Aisenberg, Harrys Torres, Jeffrey Tarrand, Amar Safdar, Gerald Bodey and Roy F. Chemaly

      Article first published online: 17 DEC 2008 | DOI: 10.1002/cncr.24011

      The clinical significance of herpes simplex virus (HSV) isolated in lower respiratory tract specimens of patients with solid tumors is unknown. In this retrospective study, the authors found that having a proven HSV pneumonia appeared to be significantly associated with increased length of stay and mechanical ventilation but had no impact on mortality rate. This subset of patients appears to benefit from acyclovir therapy.

    19. Pediatric Oncology
      You have free access to this content
      Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors (pages 207–216)

      Adam S. Levy, Paul A. Meyers, Leonard H. Wexler, Regina Jakacki, Anne Angiolillo, Sarah N. Ringuette, Marvin B. Cohen, Richard Gorlick and Other site principal investigators: Wayne Furman, MD (St. Jude Children's Research Hospital, Memphis, Tennessee); Rochelle Bagatell, MD (University of Arizona Health Sciences Center, Tucson, Arizona); Lori Luchtman-Jones, MD (Washington University School of Medicine, St. Louis, Missouri); Luis Eduardo Garcia, MD (Hospital CIMA, San Jose, Costa Rica); and Eric Sandler, MD (Nemours Children's Clinic, Jacksonville, Florida).

      Article first published online: 17 DEC 2008 | DOI: 10.1002/cncr.23992

      A recommended phase 2 dose of combination carboplatin and irinotecan was determined for previously treated pediatric patients with recurrent solid tumors. The pharmacokinetics of irinotecan are apparently not affected by concurrent carboplatin.

    20. Psychosocial Oncology
      You have free access to this content
      Marital quality and survivorship : Slowed recovery for breast cancer patients in distressed relationships (pages 217–228)

      Hae-Chung Yang and Tammy A. Schuler

      Article first published online: 24 OCT 2008 | DOI: 10.1002/cncr.23964

      Breast cancer patients were followed for 5 years after diagnosis, and associations between marital quality and psychologic, health behavior, and health outcomes were studied. Data implicate marital distress in numerous poor outcomes, calling for attention to the needs of this patient group.

    21. Symptom Control and Palliative Care
      You have free access to this content
      Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy (pages 229–232)

      Eric Vickrey, Sharon Allen, Jayesh Mehta and Seema Singhal

      Article first published online: 17 DEC 2008 | DOI: 10.1002/cncr.24006

      There is evidence from clinical trials that bortezomib therapy is associated with a significant risk of herpes zoster. In the current study, daily acyclovir (or a suitable alternative) was found to be effective at preventing herpes zoster in patients with myeloma who were receiving bortezomib, with or without corticosteroids.

SEARCH

SEARCH BY CITATION